drugset / Trial / NCT02730871
Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in subjects with open-angle glaucoma or ocular hypertension.
Timeline
- Start
- 2016-06-24
- Primary completion
- 2018-07-13
- Completion
- 2018-07-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brimonidine | Small molecule | 0.2 % | Other |
| Subject | Brinzolamide | Small molecule | 1 % | Other |
| Background | Timolol | Other / unclassified | 0.5 % | Other |
| Background | Travoprost | Other / unclassified | 0.004 % | Other |